TRCT
SUPN icon

Tower Research Capital (TRC)’s Supernus Pharmaceuticals SUPN Stock Holding History

Tower Research Capital (TRC)’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223K Buy
4,320
+2,790
+182% +$142K 0.01% 1528
2025
Q4 		$76K Sell
1,530
-1,413
-48% -$68.7K ﹤0.01% 2139
2025
Q3 		$141K Sell
2,943
-1,302
-31% -$52.4K ﹤0.01% 1747
2025
Q2 		$134K Buy
4,245
+3,051
+256% +$97.8K ﹤0.01% 2139
2025
Q1 		$39.1K Sell
1,194
-1,969
-62% -$69.8K ﹤0.01% 2406
2024
Q4 		$114K Buy
3,163
+889
+39% +$31.3K ﹤0.01% 2079
2024
Q3 		$70.9K Sell
2,274
-6,850
-75% -$214K ﹤0.01% 2508
2024
Q2 		$244K Buy
9,124
+8,726
+2,192% +$253K ﹤0.01% 1918
2024
Q1 		$13.6K Sell
398
-20,144
-98% -$600K ﹤0.01% 3382
2023
Q4 		$594K Buy
20,542
+19,168
+1,395% +$508K 0.01% 1233
2023
Q3 		$37.9K Sell
1,374
-3,037
-69% -$92.4K ﹤0.01% 2806
2023
Q2 		$133K Buy
4,411
+3,084
+232% +$108K ﹤0.01% 1852
2023
Q1 		$48K Buy
1,327
+1,056
+390% +$40.6K ﹤0.01% 2537
2022
Q4 		$9K Sell
271
-3,561
-93% -$124K ﹤0.01% 4269
2022
Q3 		$130K Buy
3,832
+1,510
+65% +$49.1K ﹤0.01% 2325
2022
Q2 		$67K Buy
2,322
+1,976
+571% +$56.6K ﹤0.01% 2623
2022
Q1 		$11K Sell
346
-2,843
-89% -$87.2K ﹤0.01% 4211
2021
Q4 		$93K Buy
3,189
+2,217
+228% +$67.3K ﹤0.01% 2275
2021
Q3 		$26K Sell
972
-1,644
-63% -$44.1K ﹤0.01% 3488
2021
Q2 		$80K Sell
2,616
-2,525
-49% -$77.4K ﹤0.01% 2604
2021
Q1 		$135K Buy
5,141
+3,406
+196% +$95.3K ﹤0.01% 2334
2020
Q4 		$44K Sell
1,735
-31,331
-95% -$674K ﹤0.01% 3232
2020
Q3 		$689K Buy
33,066
+24,308
+278% +$552K 0.01% 1333
2020
Q2 		$208K Buy
+8,758
New +$193K 0.01% 1752
2018
Q4 		– Sell
-289
Closed -$15K – 4328
2018
Q3 		$15K Buy
+289
New +$14.3K ﹤0.01% 2527
2018
Q2 		– Sell
-100
Closed -$5K – 4038
2018
Q1 		$5K Buy
+100
New +$4.17K ﹤0.01% 2727
2017
Q4 		– Sell
-2,873
Closed -$115K – 3998
2017
Q3 		$115K Buy
2,873
+2,160
+303% +$93.5K 0.01% 1224
2017
Q2 		$31K Buy
713
+613
+613% +$21.8K ﹤0.01% 992
2017
Q1 		$3K Buy
+100
New +$2.68K ﹤0.01% 2499
2016
Q1 		– Sell
-3,455
Closed -$46K – 4897
2015
Q4 		$46K Buy
3,455
+2,106
+156% +$32.6K 0.01% 611
2015
Q3 		$19K Buy
1,349
+431
+47% +$8.01K ﹤0.01% 1783
2015
Q2 		$16K Buy
918
+188
+26% +$2.68K ﹤0.01% 2297
2015
Q1 		$9K Sell
730
-5,868
-89% -$55.4K ﹤0.01% 2879
2014
Q4 		$55K Buy
6,598
+6,497
+6,433% +$54.6K 0.01% 977
2014
Q3 		$1K Buy
101
+92
+1,022% +$831 ﹤0.01% 4151
2014
Q2 		$0 Sell
9
-360
-98% -$3.21K ﹤0.01% 4623
2014
Q1 		$3K Sell
369
-1,764
-83% -$16.2K ﹤0.01% 3676
2013
Q4 		$16K Sell
2,133
-695
-25% -$4.86K ﹤0.01% 2561
2013
Q3 		$20K Sell
2,828
-7,174
-72% -$48.2K ﹤0.01% 2685
2013
Q2 		$64K Buy
+10,002
New +$58.9K 0.01% 771

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s SUPN Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Supernus Pharmaceuticals (SUPN) stake by 182% in Q1 2026, buying an estimated $142K and bringing the position to 4,320 shares worth $223K. The position accounts for 0.01% of the portfolio, ranked #1528.

Tower Research Capital (TRC) first reported a position in SUPN in Q2 2013 and has held it in 40 quarters since. The position peaked at $689K in Q3 2020. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Tower Research Capital (TRC) held 4,320 shares of Supernus Pharmaceuticals worth $223K as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,790 Supernus Pharmaceuticals shares in Q1 2026, an estimated $142K.
  • Supernus Pharmaceuticals made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1528 holding.
  • Tower Research Capital (TRC) first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 40 quarters since.
  • Tower Research Capital (TRC)'s Supernus Pharmaceuticals position peaked at $689K in Q3 2020.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.